BioCentury
ARTICLE | Company News

AbbVie, Xynomic Pharmaceuticals deal

March 3, 2017 7:48 PM UTC

Xynomic received exclusive, worldwide rights to develop and commercialize oncology candidate abexinostat from AbbVie. Xynomic said it plans to start Phase III trials of the histone deacetylase (HDAC) ...